April 28, 2021 -- Albumedix and Cobra Biologics, the gene therapy division of Cognate BioServices, will collaborate on viral vector manufacturing.
The companies will focus on upstream and downstream process optimization and stability enhancement in scale-up manufacturing of adeno-associated viruses and lentiviral vectors through proprietary recombinant human albumin-based product from Albumedix.
Financial details of the collaboration were not disclosed.